Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Protalix BioTherapeutics, Inc. (PLX - Snapshot Report) recently announced the pricing of a private placement of its convertible notes worth $60 million.

The convertible notes will mature on Sep 15, 2018 and carry an annual interest rate of 4.5% to be paid semi-annually. To cover over-allotments, the initial purchaser has been granted an option by the company of purchasing an additional $9 million worth of notes subject to the same terms and conditions. The initial purchaser will be provided a 30-day window to do so.

The notes carry an initial conversion rate of 173.6593 shares of common stock per $1,000 principal amount of Notes which is around $5.76 per share.

Protalix intends to use the funds from the offering for the development of its pipeline, enhancement of manufacturing capacity and general corporate purposes.

Protalix is dedicated to develop and commercialize proprietary, biobetter or biosimilar versions of recombinant therapeutic proteins using its proprietary ProCellEx protein expression system.

Protalix has one approved product, Elelyso/Uplyso, for the treatment of Gaucher disease in its portfolio. Protalix has a worldwide commercialization partnership (except Brazil and Israel) with Pfizer Inc. (PFE - Analyst Report) for the product.

We note that Protalix has several candidates in its pipeline which include PRX-102 (phase I/II - Fabry disease) and PRX-112 (phase I - Gaucher disease).

Furthermore, the company revealed three new compounds, PRX-106 (immune mediated disorders), PRX-110 (cystic fibrosis), and PRX-107 (emphysema), in Jun 2013.

Protalix carries a Zacks Rank #4 (Sell). Currently, companies which look attractive include Gilead Sciences Inc. (GILD - Analyst Report) and Jazz Pharmaceuticals (JAZZ - Analyst Report) with a Zacks Rank #1 (Strong Buy) and a Zacks Rank #2 (Buy), respectively.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
VERTEX ENERG VTNR 8.25 +10.59%
MODINE MANUF MOD 17.12 +8.77%
CLAYTON WILL CWEI 140.03 +7.27%
E*TRADE FINA ETFC 22.67 +5.44%
KNIGHTSBRIDG VLCCF 13.22 +5.42%